Reviews Comvax


No reviews yet.

Comvax Drug Description
COMVAX®
[Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant)
Vaccine]
DRUG DESCRIPTION



What are the possible side effects of this vaccine (Comvax)?

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with haemophilus B or hepatitis A is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any...
Read All Potential Side Effects for Comvax »




COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis
B (Recombinant) Vaccine] is a sterile bivalent vaccine made of the antigenic
components used in producing PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal
Protein Conjugate)] and RECOMBIVAX HB* [Hepatitis B Vaccine (Recombinant)].
These components are the Haemophilus influenzae type b capsular polysaccharide
[polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane
protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface
antigen (HBsAg) from recombinant yeast cultures.
Haemophilus influenzae type b and Neisseria meningitidis serogroup
B are grown in complex fermentation media. The primary ingredients of the phenol-inactivated
fermentation medium for Haemophilus influenzae include an extract of
yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose,
and mineral salts and for Neisseria meningitidis include an extract of
yeast, amino acids and mineral salts. The PRP is purified from the culture broth
by purification procedures which include ethanol fractionation, enzyme digestion,
phenol extraction and diafiltration. The OMPC from Neisseria meningitidis
is purified by detergent extraction, ultracentrifugation, diafiltration and
sterile filtration.
The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified
PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus
b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis
serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity
of the PRP. This coupling is confirmed by analysis of the components of the
conjugate following chemical treatment which yields a unique amino acid. After
conjugation, the aqueous bulk is then adsorbed onto an amorphous aluminum hydroxyphosphate
sulfate adjuvant (previously referred to as aluminum hydroxide).
HBsAg is produced in recombinant yeast cells. A portion of the hepatitis B
virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis
B is produced from cultures of this recombinant yeast strain according to methods
developed in the Merck Research Laboratories. The antigen is harvested and purified
from fermentation cultures of a recombinant strain of the yeast Saccharomyces
cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation
process involves growth of Saccharomyces cerevisiae on a complex fermentation
medium which consists of an extract of yeast, soy peptone, dextrose, amino acids
and mineral salts.
The HBsAg protein is released from the yeast cells by mechanical cell disruption and detergent extraction, and purified by a series of physical and chemical methods, which includes ion and hydrophobic chromatography, and diafiltration. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA, and 1% or less of the protein is of yeast origin.
The individual PRP-OMPC and HBsAg adjuvanted bulks are combined to produce COMVAX. Each 0.5 mL dose of COMVAX is formulated to contain 7.5 mcg PRP conjugated to approximately 125 mcg OMPC, 5 mcg HBsAg, approximately 225 mcg aluminum as amorphous aluminum hydroxyphosphate sulfate, and 35 mcg sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains not more than 0.0004% (w/v) residual formaldehyde.
The potency of the PRP-OMPC component is measured by quantitating the polysaccharide
concentration by an HPLC method. The potency of the HBsAg component is measured
relative to a standard by an in vitro immunoassay.
The product contains no preservative.
COMVAX is a sterile suspension for intramuscular injection.Last reviewed on RxList: 3/4/2009




Comvax Drug Description
COMVAX®
[Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant)
Vaccine]
DRUG DESCRIPTION



What are the possible side effects of this vaccine (Comvax)?

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with haemophilus B or hepatitis A is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any...
Read All Potential Side Effects for Comvax »




COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis
B (Recombinant) Vaccine] is a sterile bivalent vaccine made of the antigenic
components used in producing PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal
Protein Conjugate)] and RECOMBIVAX HB* [Hepatitis B Vaccine (Recombinant)].
These components are the Haemophilus influenzae type b capsular polysaccharide
[polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane
protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface
antigen (HBsAg) from recombinant yeast cultures.
Haemophilus influenzae type b and Neisseria meningitidis serogroup
B are grown in complex fermentation media. The primary ingredients of the phenol-inactivated
fermentation medium for Haemophilus influenzae include an extract of
yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose,
and mineral salts and for Neisseria meningitidis include an extract of
yeast, amino acids and mineral salts. The PRP is purified from the culture broth
by purification procedures which include ethanol fractionation, enzyme digestion,
phenol extraction and diafiltration. The OMPC from Neisseria meningitidis
is purified by detergent extraction, ultracentrifugation, diafiltration and
sterile filtration.
The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified
PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus
b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis
serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity
of the PRP. This coupling is confirmed by analysis of the components of the
conjugate following chemical treatment which yields a unique amino acid. After
conjugation, the aqueous bulk is then adsorbed onto an amorphous aluminum hydroxyphosphate
sulfate adjuvant (previously referred to as aluminum hydroxide).
HBsAg is produced in recombinant yeast cells. A portion of the hepatitis B
virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis
B is produced from cultures of this recombinant yeast strain according to methods
developed in the Merck Research Laboratories. The antigen is harvested and purified
from fermentation cultures of a recombinant strain of the yeast Saccharomyces
cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation
process involves growth of Saccharomyces cerevisiae on a complex fermentation
medium which consists of an extract of yeast, soy peptone, dextrose, amino acids
and mineral salts.
The HBsAg protein is released from the yeast cells by mechanical cell disruption and detergent extraction, and purified by a series of physical and chemical methods, which includes ion and hydrophobic chromatography, and diafiltration. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA, and 1% or less of the protein is of yeast origin.
The individual PRP-OMPC and HBsAg adjuvanted bulks are combined to produce COMVAX. Each 0.5 mL dose of COMVAX is formulated to contain 7.5 mcg PRP conjugated to approximately 125 mcg OMPC, 5 mcg HBsAg, approximately 225 mcg aluminum as amorphous aluminum hydroxyphosphate sulfate, and 35 mcg sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains not more than 0.0004% (w/v) residual formaldehyde.
The potency of the PRP-OMPC component is measured by quantitating the polysaccharide
concentration by an HPLC method. The potency of the HBsAg component is measured
relative to a standard by an in vitro immunoassay.
The product contains no preservative.
COMVAX is a sterile suspension for intramuscular injection.Last reviewed on RxList: 3/4/2009




Comvax Drug Description
COMVAX®
[Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant)
Vaccine]
DRUG DESCRIPTION



What are the possible side effects of this vaccine (Comvax)?

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with haemophilus B or hepatitis A is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any...
Read All Potential Side Effects for Comvax »




COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis
B (Recombinant) Vaccine] is a sterile bivalent vaccine made of the antigenic
components used in producing PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal
Protein Conjugate)] and RECOMBIVAX HB* [Hepatitis B Vaccine (Recombinant)].
These components are the Haemophilus influenzae type b capsular polysaccharide
[polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane
protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface
antigen (HBsAg) from recombinant yeast cultures.
Haemophilus influenzae type b and Neisseria meningitidis serogroup
B are grown in complex fermentation media. The primary ingredients of the phenol-inactivated
fermentation medium for Haemophilus influenzae include an extract of
yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose,
and mineral salts and for Neisseria meningitidis include an extract of
yeast, amino acids and mineral salts. The PRP is purified from the culture broth
by purification procedures which include ethanol fractionation, enzyme digestion,
phenol extraction and diafiltration. The OMPC from Neisseria meningitidis
is purified by detergent extraction, ultracentrifugation, diafiltration and
sterile filtration.
The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified
PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus
b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis
serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity
of the PRP. This coupling is confirmed by analysis of the components of the
conjugate following chemical treatment which yields a unique amino acid. After
conjugation, the aqueous bulk is then adsorbed onto an amorphous aluminum hydroxyphosphate
sulfate adjuvant (previously referred to as aluminum hydroxide).
HBsAg is produced in recombinant yeast cells. A portion of the hepatitis B
virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis
B is produced from cultures of this recombinant yeast strain according to methods
developed in the Merck Research Laboratories. The antigen is harvested and purified
from fermentation cultures of a recombinant strain of the yeast Saccharomyces
cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation
process involves growth of Saccharomyces cerevisiae on a complex fermentation
medium which consists of an extract of yeast, soy peptone, dextrose, amino acids
and mineral salts.
The HBsAg protein is released from the yeast cells by mechanical cell disruption and detergent extraction, and purified by a series of physical and chemical methods, which includes ion and hydrophobic chromatography, and diafiltration. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA, and 1% or less of the protein is of yeast origin.
The individual PRP-OMPC and HBsAg adjuvanted bulks are combined to produce COMVAX. Each 0.5 mL dose of COMVAX is formulated to contain 7.5 mcg PRP conjugated to approximately 125 mcg OMPC, 5 mcg HBsAg, approximately 225 mcg aluminum as amorphous aluminum hydroxyphosphate sulfate, and 35 mcg sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains not more than 0.0004% (w/v) residual formaldehyde.
The potency of the PRP-OMPC component is measured by quantitating the polysaccharide
concentration by an HPLC method. The potency of the HBsAg component is measured
relative to a standard by an in vitro immunoassay.
The product contains no preservative.
COMVAX is a sterile suspension for intramuscular injection.Last reviewed on RxList: 3/4/2009




Comvax Drug Description
COMVAX®
[Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant)
Vaccine]
DRUG DESCRIPTION



What are the possible side effects of this vaccine (Comvax)?

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with haemophilus B or hepatitis A is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any...
Read All Potential Side Effects for Comvax »




COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis
B (Recombinant) Vaccine] is a sterile bivalent vaccine made of the antigenic
components used in producing PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal
Protein Conjugate)] and RECOMBIVAX HB* [Hepatitis B Vaccine (Recombinant)].
These components are the Haemophilus influenzae type b capsular polysaccharide
[polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane
protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface
antigen (HBsAg) from recombinant yeast cultures.
Haemophilus influenzae type b and Neisseria meningitidis serogroup
B are grown in complex fermentation media. The primary ingredients of the phenol-inactivated
fermentation medium for Haemophilus influenzae include an extract of
yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose,
and mineral salts and for Neisseria meningitidis include an extract of
yeast, amino acids and mineral salts. The PRP is purified from the culture broth
by purification procedures which include ethanol fractionation, enzyme digestion,
phenol extraction and diafiltration. The OMPC from Neisseria meningitidis
is purified by detergent extraction, ultracentrifugation, diafiltration and
sterile filtration.
The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified
PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus
b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis
serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity
of the PRP. This coupling is confirmed by analysis of the components of the
conjugate following chemical treatment which yields a unique amino acid. After
conjugation, the aqueous bulk is then adsorbed onto an amorphous aluminum hydroxyphosphate
sulfate adjuvant (previously referred to as aluminum hydroxide).
HBsAg is produced in recombinant yeast cells. A portion of the hepatitis B
virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis
B is produced from cultures of this recombinant yeast strain according to methods
developed in the Merck Research Laboratories. The antigen is harvested and purified
from fermentation cultures of a recombinant strain of the yeast Saccharomyces
cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation
process involves growth of Saccharomyces cerevisiae on a complex fermentation
medium which consists of an extract of yeast, soy peptone, dextrose, amino acids
and mineral salts.
The HBsAg protein is released from the yeast cells by mechanical cell disruption and detergent extraction, and purified by a series of physical and chemical methods, which includes ion and hydrophobic chromatography, and diafiltration. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA, and 1% or less of the protein is of yeast origin.
The individual PRP-OMPC and HBsAg adjuvanted bulks are combined to produce COMVAX. Each 0.5 mL dose of COMVAX is formulated to contain 7.5 mcg PRP conjugated to approximately 125 mcg OMPC, 5 mcg HBsAg, approximately 225 mcg aluminum as amorphous aluminum hydroxyphosphate sulfate, and 35 mcg sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains not more than 0.0004% (w/v) residual formaldehyde.
The potency of the PRP-OMPC component is measured by quantitating the polysaccharide
concentration by an HPLC method. The potency of the HBsAg component is measured
relative to a standard by an in vitro immunoassay.
The product contains no preservative.
COMVAX is a sterile suspension for intramuscular injection.Last reviewed on RxList: 3/4/2009




Comvax Drug Description
COMVAX®
[Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (Recombinant)
Vaccine]
DRUG DESCRIPTION



What are the possible side effects of this vaccine (Comvax)?

Your child should not receive a booster vaccine if he or she had a life-threatening allergic reaction after the first shot.
Keep track of any and all side effects your child has after receiving this vaccine. When the child receives a booster dose, you will need to tell the doctor if the previous shots caused any side effects.
Becoming infected with haemophilus B or hepatitis A is much more dangerous to your child's health than receiving the vaccine to protect against these diseases. Like any...
Read All Potential Side Effects for Comvax »




COMVAX [Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis
B (Recombinant) Vaccine] is a sterile bivalent vaccine made of the antigenic
components used in producing PedvaxHIB* [Haemophilus b Conjugate Vaccine (Meningococcal
Protein Conjugate)] and RECOMBIVAX HB* [Hepatitis B Vaccine (Recombinant)].
These components are the Haemophilus influenzae type b capsular polysaccharide
[polyribosylribitol phosphate (PRP)] that is covalently bound to an outer membrane
protein complex (OMPC) of Neisseria meningitidis and hepatitis B surface
antigen (HBsAg) from recombinant yeast cultures.
Haemophilus influenzae type b and Neisseria meningitidis serogroup
B are grown in complex fermentation media. The primary ingredients of the phenol-inactivated
fermentation medium for Haemophilus influenzae include an extract of
yeast, nicotinamide adenine dinucleotide, hemin chloride, soy peptone, dextrose,
and mineral salts and for Neisseria meningitidis include an extract of
yeast, amino acids and mineral salts. The PRP is purified from the culture broth
by purification procedures which include ethanol fractionation, enzyme digestion,
phenol extraction and diafiltration. The OMPC from Neisseria meningitidis
is purified by detergent extraction, ultracentrifugation, diafiltration and
sterile filtration.
The PRP-OMPC conjugate is prepared by the chemical coupling of the highly purified
PRP (polyribosylribitol phosphate) of Haemophilus influenzae type b (Haemophilus
b, Ross strain) to an OMPC of the B11 strain of Neisseria meningitidis
serogroup B. The coupling of the PRP to the OMPC is necessary for enhanced immunogenicity
of the PRP. This coupling is confirmed by analysis of the components of the
conjugate following chemical treatment which yields a unique amino acid. After
conjugation, the aqueous bulk is then adsorbed onto an amorphous aluminum hydroxyphosphate
sulfate adjuvant (previously referred to as aluminum hydroxide).
HBsAg is produced in recombinant yeast cells. A portion of the hepatitis B
virus gene, coding for HBsAg, is cloned into yeast, and the vaccine for hepatitis
B is produced from cultures of this recombinant yeast strain according to methods
developed in the Merck Research Laboratories. The antigen is harvested and purified
from fermentation cultures of a recombinant strain of the yeast Saccharomyces
cerevisiae containing the gene for the adw subtype of HBsAg. The fermentation
process involves growth of Saccharomyces cerevisiae on a complex fermentation
medium which consists of an extract of yeast, soy peptone, dextrose, amino acids
and mineral salts.
The HBsAg protein is released from the yeast cells by mechanical cell disruption and detergent extraction, and purified by a series of physical and chemical methods, which includes ion and hydrophobic chromatography, and diafiltration. The purified protein is treated in phosphate buffer with formaldehyde and then coprecipitated with alum (potassium aluminum sulfate) to form bulk vaccine adjuvanted with amorphous aluminum hydroxyphosphate sulfate. The vaccine contains no detectable yeast DNA, and 1% or less of the protein is of yeast origin.
The individual PRP-OMPC and HBsAg adjuvanted bulks are combined to produce COMVAX. Each 0.5 mL dose of COMVAX is formulated to contain 7.5 mcg PRP conjugated to approximately 125 mcg OMPC, 5 mcg HBsAg, approximately 225 mcg aluminum as amorphous aluminum hydroxyphosphate sulfate, and 35 mcg sodium borate (decahydrate) as a pH stabilizer, in 0.9% sodium chloride. The vaccine contains not more than 0.0004% (w/v) residual formaldehyde.
The potency of the PRP-OMPC component is measured by quantitating the polysaccharide
concentration by an HPLC method. The potency of the HBsAg component is measured
relative to a standard by an in vitro immunoassay.
The product contains no preservative.
COMVAX is a sterile suspension for intramuscular injection.Last reviewed on RxList: 3/4/2009





Other reviews about Comvax on wordpress

Alisha is 15 months old!
  by leenaok
Alisha’s 15 month well-baby check-up was today. She is 22 lbs, 2 oz and 30 inches tall. So she’s gained around 2 ½ lbs and maybe ½ […]


Merck Vaccine Recall Q&A
  by journeytocrunchville
The following Q&A in response to the Merck Recall Vaccine was obtained from the following article. Amazingly enough (or not) I could not easily find this information on […]


Vaccine Recall
  by journeytocrunchville
Did anyone catch this very underplayed announcement? Merck has recalled 1.2 million doses of the Hib vaccine, specifically PedvaxHib and Comvax. The recall was issued because, according to Merck, […]


Merck Vaccine Recall
  by Adventure Doc
The makers of one of the Hib (Heamophilus Influenza) vaccines, Merck, have initiated a voluntary recall of certain batches of their vaccines.  The CDC has a good page […]


2 Month Checkup
  by babynar
We just got back from Sabrina's 2 month doctor appointment.  She got her first set of vaccines – DTaP (Diphtheria, Tetanus, Pertussis), Polio, Prevar (Pneumococcal bacterial infections), and […]


CDC Monitors Shortage of Hib Vaccine
  by timeinctemp
THURSDAY, Nov. 20 (HealthDay News) — U.S. health officials said Thursday that a shortage of vaccine is leading them to monitor Hib infections, one of the most important […]


Hib Vaccine Shortage in US Makes Surveillance Critical
  by fadedalley
NEW YORK (Reuters Health) Nov 20 - As a shortage of Haemophilus influenzae type b (Hib) conjugate vaccines is expected to persist until mid-2009, clinicians are advised to […]


Vaccines-What, When and How
  by noelbayang
Highlights Why are so many immunizations recommended for babies? How do immunizations work? What are the immunizations and when can I expect them? Our experts answer your most pressing questions about vaccine […]


Supply of Key Children's Vaccine Almost Back to Normal
  by timeinctemp
THURSDAY, June 25 (HealthDay News) — A children's vaccine that's been in short supply for 18 months is now being produced at levels that allow its traditional widespread […]


FDA approves Hiberix Type b (Hib) vaccine
  by davidrcurry
The U.S. Food and Drug Administration announced approval of Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years […]



Other reviews about Comvax on web:

9376602 COMVAX ® [HAEMOPHILUS b CONJUGATE (MENINGOCOCCAL PROTEIN CONJUGATE) and HEPATITIS B (RECOMBINANT) VACCINE] DESCRIPTION COMVAX * [Haemophilus b Conjugate (Meningococcal ... COMVAX [HAEMOPHILUS b CONJUGATE (MENINGOCOCCAL PROTEIN CONJUGATE ...


Learn about the prescription medication Comvax (Haemophilus b Conjugate and Hepatitis B Vaccine), drug uses, dosage, side effects, drug interactions, warnings, reviews and ... Comvax (Haemophilus b Conjugate and Hepatitis B Vaccine) Drug ...


All about Comvax Vaccine. View complete and up to date Comvax information - part of the Drugs.com trusted medication database. Comvax Vaccine Facts and Comparisons at Drugs.com


COMVAX is indicated for vaccination against invasive disease caused by Haemophilus influenzae type b and against infection caused by all known ... MerckVaccines.com


Comvax is a combination vaccine used to prevent Hib and hepatitis B. This selection from the eMedTV archives offers an overview of this product, including information on why it ... Comvax


Physician reviewed Comvax patient information - includes Comvax description, dosage and directions. Comvax medical facts from Drugs.com


Find patient medical information for Comvax IM on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Comvax IM : Uses, Side Effects, Interactions, Pictures, Warnings ...


What is Comvax (Haemophilus B Hepatitis B Vaccine)? Haemophilus B is a type of influenza (flu) caused by bacteria. Haemophilus B bacteria can infect the lungs or throat, and ... Comvax - Drugs & Treatments - Revolution Health


I've never used Comvax in my practice and I couldn't find the answer to this, so maybe someone on this list can answer my question. I just had a 12 month old transfer into my ... Comvax question


Comvax Hib-HepB, a combination vaccine that protects against the Haemophilus influenzae type B bacterium and the hepatitis B virus Comvax: Information from Answers.com





Featured Reviews

Reviews Selenium

Selsun Drug Description DRUG DESCRIPTION What are the possible side effects of selenium sulfide topical? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling...
Read More  |  Review This
Reviews Tysabri

Tysabri Drug Description TYSABRI® (natalizumab) Injection WARNING: PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of...
Read More  |  Review This
Reviews Getfitinib

Iressa Drug Description IRESSA® (gefitinib) Tablets, 250 mg DRUG DESCRIPTION What are the possible side effects of gefitinib (Iressa)? If you experience any of the following serious side effects from gefitinib, contact your...
Read More  |  Review This
Reviews Visken

Visken Drug Description Visken® (pindolol) tablets, USP DRUG DESCRIPTION What are the possible side effects of pindolol (Visken)? Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty...
Read More  |  Review This
Reviews Amlodipine Besylate and Benazepril HCl

Lotrel Drug Description Lotrel (amlodipine besylate and benazepril hydrochloride) Capsules WARNING AVOID USE IN PREGNANCY When pregnancy is detected, discontinue Lotrel as soon as possible. Drugs that act directly on the renin-angiotensin...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....